Simplifying Global Compliance
FDA: ADHD Meds Not Linked to Higher Risk of Serious Heart Events
Washington Drug Letter
The FDA will not change its recommendations for use of attention deficit hyperactivity disorder (ADHD) drugs, the agency said Dec. 12, offering data from two studies that found the drugs did not increase the risk of serious adverse cardiovascular events in adults.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing